Aspirin use to prevent cardiovascular disease and cancer: a decision analysis
Dehmer SP, Maciosek MV, Flottemesch, TJ
Record ID 32015001087
English
Authors' objectives:
To assess the net balance of benefits and harms from routine use of aspirin for primary prevention across clinically relevant age, sex, and cardiovascular disease (CVD) risk groups.
Authors' recommendations:
Benefits are predicted to exceed harms among persons aged 40-69 with nonelevated bleeding risk who take aspirin for primary prevention of CVD and CRC over their lifetimes. Net benefits from routine aspirin use over a 10- or 20-year horizon are expected to be substantially smaller, and in many cases, harms may exceed benefits. Findings do not differ markedly between men and women; however, deterministic and probabilistic sensitivity analyses reveal meaningful uncertainty about the magnitude of net benefit.
Details
Project Status:
Completed
URL for project:
http://www.ncbi.nlm.nih.gov/books/NBK321651/
Year Published:
2015
URL for published report:
http://www.ncbi.nlm.nih.gov/books/NBK321651/pdf/Bookshelf_NBK321651.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Aspirin
- Cardiovascular Diseases
- Neoplasms
- Decision Support Techniques
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.